

**ABROCITINIB tablets (Cibinqo® ▼) for atopic dermatitis**

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of ABROCITINIB tablets (Cibinqo® ▼) for atopic dermatitis.**

**GREY**

Abrocitinib is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.<sup>[1]</sup>

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, clinicians should continue to follow national guidance, local pathways and local formulary choices for the treatment of atopic dermatitis:

- > NICE Clinical Knowledge Summary (CKS): [Eczema – Atopic](#) (Last revised July 2021)
- > NICE Pathway: Eczema [Eczema](#) (Last updated 03 March 2021)
- > Pan Mersey APC Formulary: [Chapter 13 Skin – Drugs affecting the immune response](#)

**References**

1. Pfizer Ltd. Summary of Product Characteristics; [Cibinqo 100mg film-coated tablets](#), 08 September 2021. Accessed online 23 September 2021.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.